Skip to content

About
Strategy
Portfolio
Team
Advisors
Partnerships
News
Contact
Investors

◀︎ All News

Lonza and Israel Biotech Fund Enter A Collaboration Framework Agreement

May 27th, 2022 by IBF

Categories Uncategorized

Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA

© 2026 Israel Biotech Fund • Built with GeneratePress